Thermo Fisher Scientific Inc. $TMO Stock Position Cut by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,933 shares of the medical research company’s stock after selling 60 shares during the period. Trifecta Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,839,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC boosted its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. IMA Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth about $37,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. HSBC reiterated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. UBS Group raised their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $590.60.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $536.21 on Thursday. The firm has a market cap of $202.48 billion, a PE ratio of 31.01, a PEG ratio of 2.93 and a beta of 0.77. The firm’s 50 day moving average price is $486.09 and its 200 day moving average price is $448.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.